Although research on respiratory microbiomes in the context of cancer immunotherapy is relatively less extensive than that on gut microbiomes, studies have indicated that anti-PD-1 treatment can modulate the diversity and abundance of specific microbiome populations (108, 109). This evidence concerns the gene PDCD1 and cancer.